An interventional study of Pyridoxal-5'-Phosphate supplement and Placebo Supplementation in Neural Inhibition, Anxiety and Depression, sponsored by University of Reading. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 41 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by University of Reading · Not applicable, Interventional, and Basic science
Among 10 studies in Depression by University of Reading — 2 open to participants now, 3 under way, none of them phase 3. Depression · University of Reading.
Among the 10 studies in Depression by University of Reading, this one is one of 3 that started in 2026, is one of 9 with no phase, and was the 8th registered.
8,577 studies on the registry are indexed under Depression; 1,720 are open to participants now.
This study's enrollment of 44 is below the median of 81 across 7,063 interventional studies indexed under Depression.
Browse Depression studies →2 of the 10 studies in Depression by University of Reading are open now, in 1 country. Each count lists the studies.
Of the 1,088 Depression studies recruiting now, 469 (43%) set no upper age limit and 519 (48%) stop at 75 or younger; 203 take children under 18; 310 take healthy volunteers.
This study: 18 Years to 41 Years · all sexes · healthy volunteers too.
The full table on the hub →10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2026.
Median enrollment 55 across the 9 interventional studies, 318 across the 1 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
University of Reading is the lead sponsor of 150 studies on the registry; 21 are open to participants now.
2 of the studies in Depression by University of Reading that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07667530University of ReadingProbiotics for Depressive Symptomatology and Neural Activity. | 2027-03-01 |
| NCT06899607University of ReadingFibre and Mental Wellbeing Feasibility Trial | 2027-09-05 |
Among the 10 studies in Depression by University of Reading, from their registry updates:
This clinical trial investigates the effects of Vitamin B6 supplementation on neural inhibition using electroencephalography (EEG), in relation to depression and anxiety symptoms in participants from the general population with a relatively high level of symptoms at baseline. Researchers will compare a placebo group to high-dose Vitamin B6 to test the hypothesis that Vitamin B6 moves the excitation/inhibition balance towards inhibition.
The primary question this trial aims to answer is:
- Compared to placebo, in people experiencing depression and anxiety symptoms, does high-dose Vitamin B6 supplementation change the excitation/inhibition balance towards inhibition as measured using electroencephalography (EEG)?
Secondary research questions are:
8,577 studies on the registry are indexed under Depression; 1,720 are open to participants now.
This study's enrollment of 44 is below the median of 81 across 7,063 interventional studies indexed under Depression.
Browse Depression studies →University of Reading is the lead sponsor of 150 studies on the registry; 21 are open to participants now.
Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
100mg Vitamin B6 as pyridoxal-5-phosphate, daily with food
Drug: Pyridoxal-5'-Phosphate supplement
Placebo capsule, daily with food
Drug: Placebo Supplementation
100mg PLP in the form of a tablet, taken once a day for 1 week
Placebo supplement in the form of a capsule.
Neural inhibition measured using Electroencephalography
Time frame: From enrolment to the end of treatment 1 week later
Self-reported depression symptoms (Depression, Anxiety, and Stress questionnire, DASS)
Time frame: From enrolment to the end of treatment 1 week later
Self reported anxiety (Screen for Adult Anxiety Related Disorders, SCAARED)
Time frame: From enrolment to the end of treatment 1 week later
Hand grip strength
Time frame: From enrolment to the end of treatment 1 week later
Vitamin B6 status
We will quantify Vitamin B6 in capillary blood samples
Time frame: From enrolment to the end of treatment 1 week later
Plan to share: Undecided
Ran from Mar 2026 to primary completion in Sep 2026, 6 months.
Of 3,468 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 6 months is below that.
Counting every sponsor, half of 3,566 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: start May 2026 → Mar 2026, primary completion Nov 2026 → Sep 2026 and completion Nov 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.